Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Quince Therapeutics Inc (QNCX)

37 + Investors. Track Smart Money conviction in QNCX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -29
Streak
1Q ▼
Buyers last Q
26%

Smart Money Signals — QNCX

Based on 38 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their QNCX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
🔻

Below peak — only 57% of 3.0Y high

57% of all-time peak
Only 38 funds hold QNCX today versus a peak of 67 funds at 2025 Q4 — just 57% of the maximum. Low institutional ownership can mean the stock is out of favor, but it also means there's a large pool of potential buyers if sentiment turns.
📶

Steady growth — +9% more funds vs a year ago

fund count last 6Q
+3 new funds entered over the past year (+9% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🔴

Heavy selling pressure — only 26% buying

18 buying51 selling
Last quarter: 51 funds sold vs only 18 buyers. This is widespread institutional distribution — not a few funds rebalancing, but a broad exit. High conviction bearish signal.
⚠️

Fewer new buyers each quarter (-17 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 11 → 9 → 26 → 9. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

53% of holders stayed for 2+ years

■ 53% conviction (2yr+) ■ 26% medium ■ 21% new
20 out of 38 hedge funds have held QNCX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💎

Buying through price weakness — shares -25%, value -97%

Value
-96%
Shares
-24%
Last quarter: funds added -25% more shares while total portfolio value only changed -97%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
➡️

Steady discovery — ~9 new funds/quarter

6 → 11 → 9 → 26 → 9 new funds/Q
New funds entering each quarter: 11 → 9 → 26 → 9. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Veteran-anchored — 62% veterans vs 24% newcomers

■ 62% veterans ■ 14% 1-2yr ■ 24% new
Entry-cohort mix of 42 holders: 26 (62%) are 2+ year veterans, 6 entered 1–2 years ago, and 10 (24%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
📋

Smaller funds dominant — 15% AUM from top-100

15% from top-100 AUM funds
11 of 37 holders rank in the top 100 by AUM, but together hold only 15% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
3.2
out of 10
Low Exit Risk
Exit risk score 3.2/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — QNCX

In 2026 Q1, 18 hedge funds were net buyers of QNCX (9 opened a new position, 9 added to an existing one), while 51 reduced or exited (13 trimmed, 38 sold completely) — a 26% buyer ratio, indicating net institutional distribution. Net fund flow last quarter: -29 funds (more exits than new entries). Total institutional holders: 38.

Hedge Fund Ownership: QNCX

How many hedge funds hold QNCX — quarterly history vs. share price
Quarterly hedge fund ownership of QNCX vs. share price

Market Analysis: QNCX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: QNCX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Quince Therapeutics Inc (QNCX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much QNCX has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 82d ago
QNCX
-6.4%
XLV
+1.9%

QNCX outperformed XLV by -8.3% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 37d ago
QNCX
-17.8%
XLV
+3.0%

Since the filing became public, QNCX outperformed XLV by -20.8% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

5 top-rated funds 0 high-conviction
Consensus
3.4
/ 10
breadth
×
Elite
0.0
/ 10
conviction
Hedge Fund Positioning: QNCX
37 + Investors

Track Smart Money conviction in QNCX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 37 67 -44.78%
13F Shares 15M 20M -24.83%
Total Value $2M $68M -96.78%
New Positions 9 26 -17
Increased Positions 7 20 -13
Closed Positions 39 4 +35
Reduced Positions 12 5 +7
Total Calls 2 1 100.0%
Total Puts 3 1 200.0%
PUT/CALL Ratio 1.5 1.0 Bearish

Statistics: QNCX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

37 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in QNCX. Verified SEC 13F-HR filings.

QUARTER:
Top 25 QNCX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Shay Capital LLC 0.02% 1,772,909 $180K
2 Woodline Partners LP 0.00% 5,200,000 $527K
3 Intellectus Partners, LLC 0.00% 53,312 $5K
4 Nordwand Advisors, LLC 0.00% 20,000 $2K
5 ADAR1 Capital Management, LLC 0.00% 50,100 $5K
6 ADAR1 Capital Management, LLC 0.00% 50,000 $5K
7 Ieq Capital, LLC 0.00% 600,105 $61K
8 Coyle Financial Counsel LLC 0.00% 10,509 $1K
9 Millennium Management LLC 0.00% 2,503,717 $254K
10 Nixon Peabody Trust Co 0.00% 11,126 $1K
11 XTX Topco Ltd 0.00% 48,812 $5K
12 Scharf Investments, LLC 0.00% 19,461 $2K
13 Tower Research Capital LLC (TRC) 0.00% 8,740 —
14 JDM Financial Group LLC 0.00% 340 —
15 Simplex Trading, LLC 0.00% 154,093 $16K
16 Susquehanna International Group, LLP 0.00% 612,500 $61K
17 Hurley Capital, LLC 0.00% 121 —
18 Vanguard Fiduciary Trust Co 0.00% 232,326 $23K
19 Two Sigma Investments, LP 0.00% 71,223 $7K
20 Citadel Advisors LLC 0.00% 133,900 $14K
21 Susquehanna International Group, LLP 0.00% 172,640 $18K
22 Belvedere Trading LLC 0.00% 13,080 $1K
23 Mariner, LLC 0.00% 12,673 $1K
24 Westside Investment Management, Inc. 0.00% 75 —
25 Vanguard Capital Management LLC 0.00% 461,477 $47K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Quince Therapeutics Inc (QNCX)

What does the Smart Money Trend signal show for QNCX?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their QNCX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for QNCX?

Heavy selling pressure — only 26% buying: Last quarter: 51 funds sold vs only 18 buyers. This is widespread institutional distribution — not a few funds rebalancing, but a broad exit. High conviction bearish signal.

What is the fund quality score for QNCX holders?

Smaller funds dominant — 15% AUM from top-100: 11 of 37 holders rank in the top 100 by AUM, but together hold only 15% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held QNCX?

53% of holders stayed for 2+ years: 20 out of 38 hedge funds have held QNCX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Quince Therapeutics Inc (QNCX) following the 2026 Q1 hedge fund 13F filings?

As of today, QNCX has moved -17.8% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.0% for the XLV sector ETF — an outperformance of -20.8%. Since the quarter end (March 31, 2026), QNCX has gained -6.4% vs +1.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →